DexCom, Inc. DXCM
Composite 68/100; the shares have moved about 42% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 32/100 — a moderate mark against it.
Growth ranks 84/100 — a strong point in its favour. Quality ranks 82/100 — a strong point in its favour. Balance-sheet strength ranks 82/100 — a strong point in its favour.
Valuation ranks 32/100 — a moderate mark against it.
What the company does DexCom designs and sells continuous glucose monitoring (CGM) systems for diabetes management, including the Dexcom G7 and G6, as well as Stelo for prediabetes and Type 2 diabetes. Its products replace fingerstick testing and enable remote monitoring via apps like Dexcom Share and Follow.
Key financials DexCom reports strong profitability with gross, operating, and net margins of 62.5%, 24.3%, and 20.1%, respectively. ROE is 38.5% and ROCE is 31.6%, reflecting efficient capital use. Revenue grew 13.1% and EPS grew 43.6%, supported by a high Piotroski F-Score of 8/9 and Altman Z-score of 7.26.
Stock health The stock shows strong momentum with 3-month and 6-month gains of 56.19% and 34.23%, respectively, and an RSI(14) of 72.10 indicating overbought conditions. Debt/Equity is 0.53 with net debt/EBITDA at -0.39, and a current ratio of 1.73 supports liquidity.
Price vs fair value The stock trades at a **discount of 2.10%** to the analyst mean target of 93.44. - Recent headlines highlight strong YTD performance (+35%) and a 52.5% rally in 3 months (Zacks). - Analysts question whether valuation stretches can be justified despite margin momentum (Zacks). - Improved growth outlook and raised 2026 guidance are cited as key drivers (Zacks).
Looking forward Forward P/E of 34.36 and EV/EBITDA of 20.69 suggest premium valuation, while strong ROE and growth momentum may justify pricing. Continued adoption of CGM systems and expansion into prediabetes markets could support long-term upside.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.